Document Detail


Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets.
MedLine Citation:
PMID:  20691130     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lactoferrin (LF), a multifunctional glycoprotein in mammalian milk, is reported to exert a modulatory effect on lipid metabolism. The aim of the present study was to elucidate whether enteric-coated LF (eLF) might improve visceral fat-type obesity, an underlying cause of the metabolic syndrome. Using a double-blind, placebo-controlled design, Japanese men and women (n 26; aged 22-60 years) with abdominal obesity (BMI>25 kg/m2, and visceral fat area (VFA)>100 cm2) consumed eLF (300 mg/d as bovine LF) or placebo tablets for 8 weeks. Measurement of the total fat area, VFA and subcutaneous fat area from computed tomography images revealed a significant reduction in VFA ( - 14.6 cm2) in the eLF group, as compared with the placebo controls ( - 1.8 cm2; P = 0.009 by ANCOVA). Decreases in body weight, BMI and hip circumference in the eLF group ( - 1.5 kg, - 0.6 kg/m2, - 2.6 cm) were also found to be significantly greater than with the placebo (+1.0 kg, +0.3 kg/m2, - 0.2 cm; P = 0.032, 0.013, 0.041, respectively). There was also a tendency for a reduction in waist circumference in the eLF group ( - 4.4 cm) as compared with the placebo group ( - 0.9 cm; P = 0.073). No adverse effects of the eLF treatment were found with regard to blood lipid or biochemical parameters. From these results, eLF appears to be a promising agent for the control of visceral fat accumulation.
Authors:
Tomoji Ono; Michiaki Murakoshi; Noriyuki Suzuki; Norio Iida; Motoyasu Ohdera; Masaaki Iigo; Toshihide Yoshida; Keikichi Sugiyama; Hoyoku Nishino
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2010-08-09
Journal Detail:
Title:  The British journal of nutrition     Volume:  104     ISSN:  1475-2662     ISO Abbreviation:  Br. J. Nutr.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-01     Completed Date:  2011-01-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372547     Medline TA:  Br J Nutr     Country:  England    
Other Details:
Languages:  eng     Pagination:  1688-95     Citation Subset:  IM    
Affiliation:
Research and Development Headquarters, Lion Corporation, Odawara, Kanagawa, Japan. tomoono@lion.co.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adiposity / drug effects*
Adult
Anti-Obesity Agents / pharmacology,  therapeutic use*
Asian Continental Ancestry Group
Body Mass Index
Body Weight / drug effects*
Double-Blind Method
Female
Hip / anatomy & histology
Humans
Intra-Abdominal Fat / drug effects*,  metabolism
Lactoferrin / pharmacology,  therapeutic use*
Male
Middle Aged
Obesity, Abdominal / drug therapy*
Tablets, Enteric-Coated
Tomography, X-Ray Computed
Waist Circumference / drug effects
Young Adult
Chemical
Reg. No./Substance:
0/Anti-Obesity Agents; 0/Lactoferrin; 0/Tablets, Enteric-Coated

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Time-dependent changes in the expression of lymphocyte and monocyte cell adhesion molecules after me...
Next Document:  Tolerance and safety of the potentially probiotic strain Lactobacillus rhamnosus PRSF-L477: a random...